KICVentures Acquires Unique Portfolio of Synthetic Bioactive Glass for Its Newest Portfolio Company NanoFuse Biologics LLC

Share Article

KICVentures acquires NanoFuse biologic platform, broadening its portfolio to serve new growth markets.

The NanoFuse matrix technology is the next generation of biologics.

KICVentures, a Boston-based private investment firm leading in healthcare technology, announced today that it has acquired all assets of Amend Surgical Inc., offering several unique synthetic bioactive glass products and an FDA-cleared combination of demineralized bone matrix (DBM) and bioactive glass. The acquisition allows KICVentures to broaden its portfolio of biologics, positioning NanoFuse Biologics LLC to serve new markets and drive revenue growth worldwide. Amend Surgical Inc. will continue to manufacture the NanoFuse® Bioactive Matrix during the transition and focus exclusively on dental applications for the NanoFuse technology platform.

NanoFuse Bioactive Matrix is a unique and proprietary blend of DBM that combines the osteoinductive capabilities of demineralized bone with the osteostimulative properties of bioactive glass.

Results of animal studies conducted internally and by independent laboratories demonstrate that NanoFuse Bioactive Matrix performs better than other commercially available bone void filler implant preparations that include only DBM. Additionally, the calcium-based bioactive glass used in NanoFuse Bioactive Matrix allows production of an exceedingly strong interfacial bond between the graft and adjacent bony tissue within minutes.

“The NanoFuse matrix technology is the next generation of biologics, which, unlike any biologic on the market, offers surgeons the synergistic combination of bioactive glass and demineralized allograft bone in a single product,” said KICVentures Founder and CEO, Orthopedic Surgeon Dr. Kingsley R. Chin. “The NanoFUSE matrix will come in a variety of configurations, offered as either a combination synthetic plus DBM or fully synthetic product - both of which KICVentures has the exclusive global rights to.”

About KICVentures
KICVentures is a private investment company founded in 2005 by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities, headquartered in Boston, Mass.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Abagail Sullivan
Visit website